GLP-1 Receptor Agonists in Glaucoma Care

Glaucoma exists at the intersection of vascular dysregulation, metabolic stress, and neurodegeneration.

Category	Detail
Condition	Primary open-angle glaucoma (POAG)
Key Mechanisms	Neuroprotection, anti-inflammatory effects, reduction of oxidative stress, protection of retinal ganglion cells, modulation of vascular autoregulation and neuroinflammatory pathways
Target Population	Patients with type 2 diabetes at risk for or with glaucoma
Care Setting	Eye care clinics, optometry and ophthalmology practices

GLP-1 receptor agonists are associated with a lower risk of developing POAG compared to metformin in diabetic patients.
These agents cross the blood-brain and blood-retina barriers, reducing retinal inflammation and neuronal death linked to glaucoma.
The protective effect appears early in disease progression, suggesting potential stabilization of vascular and neuroinflammatory processes.

Screen and monitor glaucoma in patients with diabetes, considering systemic medication profiles.

Recognize GLP-1 receptor agonists as potential neuroprotective agents beyond glycemic control.
Continue standard glaucoma management; GLP-1 receptor agonists are not currently prescribed specifically for glaucoma.

Observe optic nerve health and glaucoma progression in patients on GLP-1 receptor agonists.
Monitor systemic metabolic health as it relates to glaucoma risk.

Current evidence is observational; causality between GLP-1 receptor agonists and glaucoma risk reduction is not established.

Patients with type 2 diabetes using GLP-1 receptor agonists versus metformin

GLP-1 receptor agonists may confer additional neuroprotective benefits reducing glaucoma risk compared to metformin alone.

Be attentive to patients’ systemic medications when assessing glaucoma risk.
Consider the emerging metabolic-glaucoma connection in clinical evaluations.
Educate patients on the potential ocular benefits of systemic diabetes therapies.